Alpha 2.0
Login Register
» Authors » Jinqin Liu

Jinqin Liu

Explore the profile of Jinqin Liu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 260
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Zhijian Xiao
Bing Li
Zefeng Xu
Tiejun Qin
Shiqiang Qu
Lijuan Pan
Gang Huang
Robert Peter Gale
Yue Zhang
Huijun Huang
Published In
Blood Cancer J
Br J Haematol
Hematol Oncol
Exp Hematol Oncol
Oncotarget
Affiliations
Soon will be listed here.
Recent Articles
1.
Structures and Biological Activities of Secondary Metabolites from spp
Chen W, Yu M, Chen S, Gong T, Xie L, Liu J, et al.
J Fungi (Basel) . 2024 Mar; 10(3). PMID: 38535199
The fungus genus is an important source of drug discoveries in scientific fields and in the pharmaceutical industry due to its potential to produce a variety of structured novel and...
2.
Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
Huang H, Liu J, Yang L, Yan Y, Chen M, Li B, et al.
Blood Sci . 2023 Nov; 5(4):258-268. PMID: 37941916
Ruxolitinib is a cornerstone of management for some subsets of myeloproliferative neoplasms (MPNs); however, a considerable number of patients respond suboptimally. Here, we evaluated the efficacy of micheliolide (MCL), a...
3.
Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and rearrangement
Yan Y, Qu S, Liu J, Li C, Yan X, Xu Z, et al.
Leuk Lymphoma . 2023 Jun; 64(9):1605-1610. PMID: 37354441
No abstract available.
4.
Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
Yan X, Xu Z, Zhang P, Sun Q, Jia Y, Qin T, et al.
Blood Cancer J . 2023 Apr; 13(1):56. PMID: 37080954
No abstract available.
5.
Case of cryptic rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
Qu S, Yan Y, Li C, Xu Z, Cai W, Qin T, et al.
Leuk Res Rep . 2023 Mar; 19:100367. PMID: 36968263
For a long time, fusion seems to be the only cryptic rearrangement of myeloid/lymphoid neoplasm with tyrosine kinase gene fusions. Recently, with the wide application of RNA sequencing, more cryptic...
6.
Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates
Wu J, Zhang W, Zhang P, Qin T, Xu Z, Sun Q, et al.
Hematol Oncol . 2022 Oct; 41(3):598-602. PMID: 36265165
No abstract available.
7.
mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
Shi Z, Liu J, Zhao Y, Yang L, Cai Y, Zhang P, et al.
Haematologica . 2022 Aug; 108(5):1359-1373. PMID: 36005555
Apart from the central role of the activated JAK/STAT signaling pathway, ASXL1 mutations are the most recurrent additional mutations in myeloproliferative neoplasms and occur much more commonly in myelofibrosis than...
8.
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy
Liu Y, Kwon J, Fabiani E, Xiao Z, Liu Y, Follo M, et al.
N Engl J Med . 2022 May; 386(21):1998-2010. PMID: 35613022
Background: Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated. Methods: We examined the effect of...
9.
Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center
Liu D, Xu Z, Zhang P, Qin T, Sun X, Qu S, et al.
Haematologica . 2022 Jan; 107(4):991-995. PMID: 34989218
No abstract available.
10.
Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
Liu D, Xu Z, Zhang P, Qin T, Li B, Qu S, et al.
Blood Cancer J . 2021 Sep; 11(9):154. PMID: 34535626
No abstract available.